Atomoxetine Open-Label Trial in ADHD
Atomoxetine (originally named tomoxetine), a new therapy for attention deficit hyperactivity disorder (ADHD) marketed by Eli Lilly, was compared to methylphenidate in a prospective, randomized, open-label study for 10 weeks duration, at the University of Nebraska Medical Center, Massachusetts Genera...
Сохранить в:
| Главный автор: | |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Pediatric Neurology Briefs Publishers
2002-07-01
|
| Серии: | Pediatric Neurology Briefs |
| Предметы: | |
| Online-ссылка: | https://www.pediatricneurologybriefs.com/articles/1610 |
| Метки: |
Нет меток, Требуется 1-ая метка записи!
|